[go: up one dir, main page]

MX2017001263A - Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. - Google Patents

Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.

Info

Publication number
MX2017001263A
MX2017001263A MX2017001263A MX2017001263A MX2017001263A MX 2017001263 A MX2017001263 A MX 2017001263A MX 2017001263 A MX2017001263 A MX 2017001263A MX 2017001263 A MX2017001263 A MX 2017001263A MX 2017001263 A MX2017001263 A MX 2017001263A
Authority
MX
Mexico
Prior art keywords
polypeptides
cancer
prevention
treatment
nucleic acids
Prior art date
Application number
MX2017001263A
Other languages
English (en)
Other versions
MX356502B (es
Inventor
Lahoutte Tony
DEVOOGDT Nick
D'huyvetter Matthias
de vos Jens
Original Assignee
Univ Brussel Vrije
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brussel Vrije filed Critical Univ Brussel Vrije
Publication of MX2017001263A publication Critical patent/MX2017001263A/es
Publication of MX356502B publication Critical patent/MX356502B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La solicitud proporciona polipéptidos que comprenden o consisten esencialmente en al menos un dominio variable de cadena pesada de un anticuerpo de cadena pesada (VHH) o fragmentos funcionales del mismo, en donde el VHH o fragmento funcional del mismo se une específicamente a una proteína objetivo que está presente en y/o específica para un tumor sólido o una célula cancerosa, por ejemplo HER2. La solicitud proporciona además ácidos nucleicos que codifican para tales polipéptidos; métodos para preparar los polipéptidos; células hospederas que expresan o son capaces de expresar los polipéptidos; composiciones y, en particular, composiciones farmacéuticas que comprenden los polipéptidos, ácidos nucleicos y/o células hospederas. La solicitud proporciona además los polipéptidos, ácidos nucleicos, células hospederas y/o composiciones, para usarse en métodos para la prevención y/o tratamiento de cáncer.
MX2017001263A 2014-07-29 2015-07-17 Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. MX356502B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14178943 2014-07-29
PCT/EP2015/066430 WO2016016021A1 (en) 2014-07-29 2015-07-17 Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017001263A true MX2017001263A (es) 2017-08-10
MX356502B MX356502B (es) 2018-05-31

Family

ID=51225425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001263A MX356502B (es) 2014-07-29 2015-07-17 Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.

Country Status (11)

Country Link
US (1) US9855348B2 (es)
EP (2) EP3174559B1 (es)
JP (1) JP6289733B2 (es)
KR (1) KR101820029B1 (es)
CN (1) CN106573983B (es)
AU (1) AU2015295687C1 (es)
CA (1) CA2954359C (es)
DK (1) DK3174559T3 (es)
FI (1) FI3174559T3 (es)
MX (1) MX356502B (es)
WO (1) WO2016016021A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810197B1 (en) * 2012-02-02 2018-04-04 Brainlab AG Method for determining an infusion parameter
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
JP6917357B2 (ja) 2015-07-17 2021-08-11 フレイエ ユニヴェルシテイト ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ 癌治療に使用する放射標識抗体断片
WO2018178936A1 (en) * 2017-03-30 2018-10-04 Duke University Radiolabeled biomolecules and their use
US11324474B2 (en) * 2018-09-13 2022-05-10 Canon Medical Systems Corporation Medical image diagnostic system and radiation dose management apparatus
CA3185968A1 (en) 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
EP3967674A1 (en) * 2020-09-11 2022-03-16 Precirix N.V. Reactions of radioactive compounds facilitated by a solid phase
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
CN117670883B (zh) * 2024-01-31 2024-05-07 中国医学科学院北京协和医院 一种鉴别高低级别膀胱癌的方法、设备和系统
FR3160407A1 (fr) * 2024-03-25 2025-09-26 Gcs Institut De Cancerologie Strasbourg Europe Complexe peptidique radiosensibilisant

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0784684B8 (en) 1994-09-16 2008-03-26 Cancer Research Institute of Contra Costa RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP0937140B1 (en) 1996-06-27 2007-09-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Antibody molecules which interact specifically with the active site or cleft of a target molecule
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
WO2000065057A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
ES2368623T3 (es) 2000-12-13 2011-11-18 Bac Ip B.V. Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
MX2010005783A (es) * 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins

Also Published As

Publication number Publication date
AU2015295687B2 (en) 2018-02-15
DK3174559T3 (da) 2022-12-05
FI3174559T3 (fi) 2023-01-13
EP3174559B1 (en) 2022-10-19
EP3174559A1 (en) 2017-06-07
AU2015295687C1 (en) 2019-10-17
CN106573983B (zh) 2018-05-25
WO2016016021A1 (en) 2016-02-04
KR101820029B1 (ko) 2018-02-28
US9855348B2 (en) 2018-01-02
CA2954359A1 (en) 2016-02-04
JP2017528435A (ja) 2017-09-28
BR112017001782A2 (pt) 2017-11-21
CA2954359C (en) 2018-09-25
MX356502B (es) 2018-05-31
CN106573983A (zh) 2017-04-19
JP6289733B2 (ja) 2018-03-07
EP3718574A1 (en) 2020-10-07
KR20170032463A (ko) 2017-03-22
AU2015295687A1 (en) 2017-03-02
US20160030606A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MX2017001263A (es) Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
SG10201810507WA (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EP4282881A3 (en) Antibodies against csf-1r
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
EA201892774A1 (ru) Антитела
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
HK1254880A1 (zh) 抗pd-1抗体及其应用
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
WO2018069871A3 (en) Anti-kras binding proteins
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
GEAP202114876A (en) ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
MX2023002591A (es) Interfaces de proteina.
BR112017003487A2 (pt) ?anticorpo totalmente humano, fragmento de fab de anticorpo totalmente humano, anticorpo humano de fita simples, anticorpo de fita simples totalmente humano, método de tratamento de amplo espectro de cânceres e método de tratamento de distúrbios inflamatórios?
EA201591898A1 (ru) Антитела, направленные на m-csf
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.

Legal Events

Date Code Title Description
FG Grant or registration